Why wait to prescribe TRELEGY for your patients with ASTHMA who remain symptomatic on an ICS/LABA?

Meet

CRAIG

a patient with ASTHMA

40-year-old adherent on a
MEDIUM-DOSE ICS/LABA

Lungs icon

Meet

LIZ

a patient with ASTHMA

48-year-old treated with a
HIGH-DOSE ICS/LABA

Lungs icon

You may have patients who remain symptomatic with current ASTHMA therapy

Asthma symptoms icon

Of patients with ASTHMA treated with a medium- or high-dose ICS/LABA,

30% - 50%

reported inadequately controlled ASTHMA (ACT ≤19) even
when treatment adherence was optimal1-5


Based on data from 3 randomized controlled trials (N=2431) and a real-world study (N=428). For the randomized controlled trials, >90% of patients were >80% adherent. For the real-world study, only patients with self-reported moderate to high adherence according to the MMAS were included.1-5

The 2024 GINA Report includes single-inhaler triple therapy as an option for adult patients with ASTHMA who are not well controlled on a medium- or high-dose ICS/LABA.6

Uncovering unreported
symptoms

Careful questioning may reveal
poorly controlled ASTHMA, so
look for:

  • Frequency of ASTHMA symptoms6
  • Any limitations to activities6
  • Nighttime awakenings6
  • How often the patient refills rescue
    medication6

A short test to assess ASTHMA
control

Learn about a tool to help track ASTHMA
control in your patients.

 

Identify undertreated patients with
ASTHMA earlier

Undertreated ASTHMA can lead to uncontrolled symptoms, loss of lung function, and exacerbations.6

Craig in workshop

 

See how much TRELEGY improved
lung function in adult patients
with ASTHMA.

See head-to-head data

 

Help your patients
try TRELEGY.

Request samples now

 

What is the starting dose of
TRELEGY for adult patients with
ASTHMA?

See dosing considerations

See TRELEGY efficacy data vs
an ICS/LABA in adults with
ASTHMA.

Learn more

INDICATIONS & IMPORTANT SAFETY INFORMATION
INDICATIONS

INDICATIONS

  • COPD: TRELEGY 100/62.5/25 is for maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
  • Asthma: TRELEGY is for maintenance treatment of adults with asthma.

Limitations of Use: TRELEGY is NOT for the relief of acute bronchospasm.

  • COPD: TRELEGY 100/62.5/25 is for maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
  • Asthma: TRELEGY is for maintenance treatment of adults with asthma.

Limitations of Use: TRELEGY is NOT for the relief of acute bronchospasm.

IMPORTANT SAFETY INFORMATION

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

TRELEGY is contraindicated in the following:

  • Primary treatment of status asthmaticus or other acute episodes of COPD or asthma where intensive measures are required.

CONTRAINDICATIONS

TRELEGY is contraindicated in the following:

  • Primary treatment of status asthmaticus or other acute episodes of COPD or asthma where intensive measures are required.
  • Patients with severe hypersensitivity to milk proteins or demonstrated hypersensitivity to fluticasone furoate (FF), umeclidinium (UMEC), vilanterol (VI), or any of the excipients.